Zenara Pharma launches Paxlovid generic for COVID-19 in India
The drug reduces the risk of death or hospitalisation by 89 per cent
Zenara Pharma, a subsidiary of Biophore India Pharma, has launched Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild-to-moderate symptoms of COVID-19. Zenara Pharma has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market this product last month. The tablet, which will be sold under the brand name ‘Paxzen,’ is being manufactured at Zenara’s US FDA and EU approved state-of-the-art facility in Hyderabad, as per a statement from Zenara Pharma.
The product will be sold at a Maximum Retail Price (MRP) of Rs 5,200 per box, equivalent to one full course of treatment per patient, and contains 20 tablets of Nirmatrelvir 150ml and 10 tablets of Ritonavir 100mg, the statement added.
Dr Jagadeesh Babu Rangisetty, co-founder and Managing Director, Zenara Pharma, said in the statement, “We have launched this product in India with an aim to bring the best treatment options against COVID within reach of patients in our country. Our product, Paxzen, has been proven equivalent to Paxlovid through a bioequivalence study, based on which we have received the approval from the regulatory authorities.”
This product’s breakthrough approval in the US was given by the US FDA in Dec 2021. It was the first oral pill that has been approved by the US FDA, and with a better safety profile than subsequently approved oral therapies and can be self-administered at home, when prescribed. Studies also indicate that the risk of death or hospitalisation is reduced by 89 per cent when taken in a timely manner against COVID, the statement concluded.